|
Antibiotics to Reduce Chorioamnionitis-Related Perinatal HIV Transmission Clinical Trials Resources presented on Clinical Trials Search is not meant to be a substitute for proven health advice, calls or treatment with a real medical. We aren't mDs. Always consult your doctor on Antibiotics to Reduce Chorioamnionitis-Related Perinatal HIV Transmission conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Antibiotics to Reduce Chorioamnionitis-Related Perinatal HIV Transmission Clinical research trials and Antibiotics to Reduce Chorioamnionitis-Related Perinatal HIV Transmission healthcare trials take place in a lot of of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectiveness of new does drugs. The function of the studies / projects is to figure out specific human medical questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to find cures for all varieties of conditions, like Antibiotics to Reduce Chorioamnionitis-Related Perinatal HIV Transmission. Antibiotics to Reduce Chorioamnionitis-Related Perinatal HIV Transmission Clinical Trials and other clinical trials allow volunteers to access health treatment options before they are available to the masses. Many times the subjects receive professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Antibiotics to Reduce Chorioamnionitis-Related Perinatal HIV Transmission clinical trial. Human subjects often obtain the finest healthcare possible for their Antibiotics to Reduce Chorioamnionitis-Related Perinatal HIV Transmission condition. Hazards are a reality, nevertheless, and might include additional or frequent dr. calls, health hazards (potentially life-jeopardizing), and/or the treatment being uneffective. Trials are federally regulated with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > Antibiotics to Reduce Chorioamnionitis-Related Perinatal HIV Transmission  Antibiotics to Reduce Chorioamnionitis-Related Perinatal HIV Transmission
Antibiotics to Reduce Chorioamnionitis-Related Perinatal HIV Transmission
For Condition: HIV Infections
Status: No longer recruiting
Sponsor(s): National Institute of Child Health and Human Development (NICHD) , National Institute of Allergy and Infectious Diseases (NIAID),National Institute of Mental Health (NIMH),National Institute on Drug Abuse (NIDA)
Synopsis: The purpose of this study is to see if antibiotic drugs given to treat an infection of the uterus during pregnancy can reduce the chances of HIV being passed from an HIV-positive mother to her baby. A link between bacterial disease of the vagina, premature birth, infection of the uterus during pregnancy, and the passing of HIV from a mother to her baby has been found. Early treatment of these problems may reduce the risk of passing HIV from an HIV-positive mother to her baby. [Note: As of 02/21/03, enrollment into this study was halted because preliminary data showed that the study antibiotics were not effective in preventing mother-to-child HIV transmission.]
Details: Obstetric risk factors for HIV maternal-child transmission (MCT) include preterm birth, prolonged rupture of the membranes, and chorioamnionitis. Many preterm births are associated with and likely caused by chorioamnionitis. The relationship between bacterial vaginosis, preterm birth, histologic chorioamnionitis, and perinatal transmission of HIV has been consistently demonstrated. Perinatal HIV transmission is more common in preterm infants, and there is now evidence that subclinical chorioamnionitis is a substantial risk factor for MCT. For this study, the primary hypothesis is that early and appropriate treatment of subclinical chorioamnionitis prior to the onset of spontaneous preterm labor, and/or antibiotic treatment during labor, to prevent premature rupture of membrane-associated-chorioamnionitis, will reduce the risk of perinatal HIV transmission. [Note: As of 02/21/03, enrollment into this study was halted because preliminary data showed that the study antibiotics were not effective in preventing mother-to-child HIV transmission.] At 20 to 24 weeks, women who are randomized to receive antibiotics receive metronidazole and erythromycin for 7 days. Women randomized to the control group receive identically appearing placebos. With the onset of contractions and/or premature rupture of membranes, study participants will initiate a second oral course of antibiotics consisting of metronidazole and ampicillin or placebo every 4 hours, continuing after delivery until the course is completed. All HIV-infected women and their neonates will be offered the HIVNET 012 nevirapine (NVP) regimen. If the mother accepts the NVP for herself and her baby, she will be given 1 dose of NVP to be taken at onset of labor, and her baby will receive 1 dose of NVP at 72 hours post-birth or discharge, whichever occurs earlier. If the mother refuses NVP or is uninfected, she will receive a matched placebo at the 26- to 30-week visit to preserve participant confidentiality. This study takes place in Blantyre and Lilongwe, Malawi, in Lusaka, Zambia, and in Dar es Salaam, Tanzania.
Eligibility:
Study Type: Interventional, Prevention, Double-Blind, Efficacy Study
Minimum Age/Maximum Age: /
Genders: Female
Protocol Entry Criteria: Inclusion Criteria - HIV positive. - 20 to 24 weeks pregnant. - Willing to take the planned antibiotic treatment. - Planning to deliver at 1 of the study sites. - Willing to come back for follow-up visits for 1 year after the baby is born. Exclusion Criteria - Have taken antibiotics, except for syphilis or gonorrhea, within the last 2 weeks. - Are allergic to penicillin, ampicillin, erythromycin, or metronidazole. - Have major illnesses, such as diabetes, severe kidney or heart disease, or active tuberculosis, which might affect the pregnancy. - Are having major problems with the pregnancy, such as placenta previa, ruptured membranes, or multiple pregnancy. - Have a central nervous system disease, such as seizures. - Are taking anticoagulant drugs.
Total Enrollment: 3720
Location and Contact Information:
Overall Study Official:
TahaTaha, Study Chair, Johns Hopkins University
Megan Valentine
Research Triangle Park, North Carolina, 27709
United States
Additional Information:
Study ID Numbers: HIVNET 024;
Study Start Date:
Record last reviewed: March 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00021671
Other Hiv Infections Studies:
1. A Comparison of Three Drug Combinations Containing Clarithromycin in the Treatment of Mycobacterium Avium Complex (MAC) Disease in Patients with AIDS
2. Vitamin A Therapy for Tuberculosis
3. A Study of Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia (PCP) in HIV-Infected Children Who Cannot Take Trimethoprim-Sulfamethoxazole
4. A Phase I Trial of Tecogalan sodium (DS-4152) Administered as an Infusion Every 21 Days
5. A Study to Evaluate High Protein Supplementation in HIV-Positive Patients with Stable Weight Loss
Related Studies:
Other HIV Infections Clinical Trials
Other North Carolina Clinical Trials
Other Research Triangle Park Clinical Trials
Antibiotics to Reduce Chorioamnionitis-Related Perinatal HIV Transmission
|
|
|
|
|
|
|
|
